Safety, Pharmacokinetic, and Pharmacodynamic Study of NKTT120 in Adult Patients With Stable Sickle Cell Disease (SCD)

Phase 1 Completed 21 enrolled NKT Therapeutics

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the safety, pharmacokinetics, and pharmacodynamics of NKTT120 in adult patients with stable sickle cell disease.

Timeline

Start: 2013-02
Primary completion: 2015-05
Completion: 2015-05

Publications

Field JJ, Majerus E, Ataga KI, Vichinsky EP, Schaub R, Mashal R, Nathan DG. NNKTT120, an anti-iNKT cell monoclonal antibody, produces rapid and sustained iNKT cell depletion in adults with sickle cell disease. PLoS One. 2017 Feb 2;12(2):e0171067. doi: 10.1371/journal.pone.0171067. eCollection 2017.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	NKTT120	Monoclonal antibody	0.001 mg/kg	Intravenous
Subject	NKTT120	Monoclonal antibody	0.1 mg/kg	Intravenous
Subject	NKTT120	Monoclonal antibody	0.3 mg/kg	Intravenous
Subject	NKTT120	Monoclonal antibody	1 mg/kg	Intravenous

Safety, Pharmacokinetic, and Pharmacodynamic Study of NKTT120 in Adult Patients With Stable Sickle Cell Disease (SCD)

Summary

Timeline

Publications

Drugs

Indications